Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

Early-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Li-Chung, Lin, Shu-Min, Lo, Yu-Lun, Kuo, Scott Chih-Hsi, Yang, Cheng-Ta, Hsu, Ping-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310081/
https://www.ncbi.nlm.nih.gov/pubmed/34201650
http://dx.doi.org/10.3390/vaccines9070689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310081/
https://www.ncbi.nlm.nih.gov/pubmed/34201650
http://dx.doi.org/10.3390/vaccines9070689

Ejemplares similares